文章预览
SCI 29 March 2025 Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemoimmunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON) (Journal of Thoracic Oncology, IF: 21.1) Taiki Hakozaki, Kentaro Tanaka, Yoshimasa Shiraishi, Yuta Sekino, Noriko Mitome, Yusuke Okuma, Tomoiki Aiba, Takahiro Utsumi, Junko Tanizaki, Koichi Azuma, Satoshi Hara, Ryo Morita, Seiji Niho, Toshihide Yokoyama, Ryo Toyozawa, Hidehito Horinouchi, Isamu Okamoto, Yukio Hosomi, Yuichiro Ohe CORRESPONDENCE TO: t-hakozaki@akane.waseda.jp Background 背景 Immunotherapy has transformed treatment for non-small cell lung cancer (NSCLC). However, reliable biomarkers for treatment selection remain scarce. Gut microbiota has emerged as a potential biomarker, but its role in chemo-immunotherapy for NSCLC is unclear. 免疫治疗已经改变了非小细胞肺癌（NSCLC）的治疗方式。然而，选择可靠的治疗生物标志物仍然稀缺。肠道菌群作为潜在的生物
………………………………
